Hepatitis C News

Results of a prospective study showed that treatment with direct-acting antivirals for hepatitis C correlated with significantly reduced risks for hepatocellular carcinoma and mortality, according to a study published in The Lancet.

As researchers continue to focus on hard-to-reach populations for hepatitis C testing and treatment, the ongoing opioid epidemic presents an opportunity for prevention as treatment through outreach and education in the regions with highest injection drug use.

Low levels of free testosterone are common among men with chronic hepatitis C infection following SVR and persist after HCV clearance, according to findings from a prospective, longitudinal cohort study.

More than two-thirds of patients with hepatitis C who visited a Federally Qualified Health Center in Philadelphia were linked to care, including both antibody and RNA testing, and many continued to medical evaluation, according to a study published in Hepatology.

Among the three largest Hispanic population subgroups, researchers found high levels of heterogeneity in chronic liver disease-related mortality patterns, according to a recently published study.

Patients undergoing direct-acting antiviral therapy for hepatitis C who had non-characterized liver nodules had a higher risk for hepatocellular carcinoma within a short follow-up time than other patients, according to a recently published study.

As defined by WHO targets, the goal to eliminate hepatitis C virus globally by 2030 will be “narrowly missed,” but is possible by 2032 using new tools and “ambitious, integrated interventions,” study findings showed.

Lincoln Financial Group and the American Liver Foundation have joined together to raise awareness of hepatitis C in the U.S. and improve educational resources, according to a press release.

Between 2010 and 2017, the number and percentage of deceased donor organs with a transmissible infectious disease — such as hepatitis C, hepatitis B or HIV — increased in the U.S., which may likely be tied to the ongoing opioid epidemic, according to a recent report from the CDC.

Patients with complete response to hepatocellular carcinoma and underwent direct-acting antiviral therapy for hepatitis C had similar rates of cancer recurrence compared with patients who did not receive DAA therapy, according to a study published in Gastroenterology.